Clinical trial
A Phase 2 Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients
NCT05479981 is registered in ClinicalTrials.gov with Avidity Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients
- Lead sponsor
- Avidity Biosciences, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 4, 2022
- Completion date
- September 10, 2025
- Enrollment
- 37 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
dm1, genetic diseases, inborn, heredodegenerative disorders, nervous system, muscular diseases, muscular disorders, atrophic, muscular dystrophies, musculoskeletal diseases, myotonic disorders, myotonic dystrophy, myotonic dystrophy 1, nervous system diseases, neurodegenerative diseases, neuromuscular diseases